Tri Locum Partners LP Sells 332,621 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Tri Locum Partners LP reduced its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,423,116 shares of the company's stock after selling 332,621 shares during the quarter. Teva Pharmaceutical Industries accounts for about 11.1% of Tri Locum Partners LP's investment portfolio, making the stock its largest holding. Tri Locum Partners LP owned about 0.21% of Teva Pharmaceutical Industries worth $53,405,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Diversify Advisory Services LLC lifted its holdings in Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after acquiring an additional 496 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares during the period. Townsquare Capital LLC grew its stake in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares during the last quarter. Metis Global Partners LLC increased its position in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after buying an additional 860 shares during the period. Finally, DGS Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after buying an additional 872 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of a number of analyst reports. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.66 during trading on Friday, hitting $16.28. The company had a trading volume of 5,991,123 shares, compared to its average volume of 9,940,767. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The business's 50-day moving average is $15.11 and its 200 day moving average is $17.51. The company has a market cap of $18.45 billion, a P/E ratio of -11.20, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.